http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103476410-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-80 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4178 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-537 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2009 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-537 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-41 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-80 |
| filingDate | 2012-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103476410-B |
| titleOfInvention | combination therapy |
| abstract | The present invention relates to a pharmaceutical composition comprising: a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof, and b) at least one chemokine receptor pathway inhibitor or its Pharmaceutically acceptable salts. The present invention also relates to a pharmaceutical composition comprising: a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof; and b) at least one inhibitor other than a chemokine receptor A chemokine receptor pathway inhibitor of a chemokine receptor pathway component or a pharmaceutically acceptable salt thereof. Oral sustained release pharmaceutical compositions comprising the pharmaceutical compositions are described, as well as injectable sustained release pharmaceutical compositions comprising the pharmaceutical compositions. The present invention further relates to tablets, capsules, injectable suspensions and compositions for pulmonary or nasal delivery comprising the pharmaceutical compositions. Also described are methods of assessing the efficacy of the pharmaceutical compositions; methods of assessing the inhibitory or partially inhibitory activity of the pharmaceutical compositions; methods of treating, ameliorating or preventing a condition or disease comprising administering to a subject a therapeutically effective amount and the use of the pharmaceutical composition in the preparation of a dosage form for treating a disease. |
| priorityDate | 2011-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 459.